DK3668856T3 - Hidtil ukendte tetrazolforbindelser og anvendelse deraf til behandling af tuberkulose - Google Patents

Hidtil ukendte tetrazolforbindelser og anvendelse deraf til behandling af tuberkulose Download PDF

Info

Publication number
DK3668856T3
DK3668856T3 DK18755815.0T DK18755815T DK3668856T3 DK 3668856 T3 DK3668856 T3 DK 3668856T3 DK 18755815 T DK18755815 T DK 18755815T DK 3668856 T3 DK3668856 T3 DK 3668856T3
Authority
DK
Denmark
Prior art keywords
tuberculosis
treatment
tetrazole compounds
novel tetrazole
novel
Prior art date
Application number
DK18755815.0T
Other languages
English (en)
Inventor
Carlos Alemparte-Gallardo
Lourdes Encinas
Provencio Jorge Esquivias
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Application granted granted Critical
Publication of DK3668856T3 publication Critical patent/DK3668856T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK18755815.0T 2017-08-17 2018-08-16 Hidtil ukendte tetrazolforbindelser og anvendelse deraf til behandling af tuberkulose DK3668856T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382574 2017-08-17
PCT/EP2018/072205 WO2019034729A1 (en) 2017-08-17 2018-08-16 NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

Publications (1)

Publication Number Publication Date
DK3668856T3 true DK3668856T3 (da) 2021-09-20

Family

ID=59713960

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18755815.0T DK3668856T3 (da) 2017-08-17 2018-08-16 Hidtil ukendte tetrazolforbindelser og anvendelse deraf til behandling af tuberkulose

Country Status (19)

Country Link
US (1) US11072591B2 (da)
EP (1) EP3668856B1 (da)
JP (1) JP7410017B2 (da)
KR (1) KR102661367B1 (da)
CN (1) CN110997651B (da)
AU (1) AU2018317812C1 (da)
BR (1) BR112020003247A2 (da)
CA (1) CA3072854A1 (da)
CY (1) CY1124577T1 (da)
DK (1) DK3668856T3 (da)
ES (1) ES2885573T3 (da)
HR (1) HRP20211326T1 (da)
HU (1) HUE055732T2 (da)
LT (1) LT3668856T (da)
PL (1) PL3668856T3 (da)
PT (1) PT3668856T (da)
RS (1) RS62267B1 (da)
SI (1) SI3668856T1 (da)
WO (1) WO2019034729A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN115403533B (zh) * 2021-05-28 2023-08-25 永康市第一人民医院 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK262000A3 (en) * 1997-07-22 2001-01-18 Shionogi & Co Therapeutic or prophylactic agent for glomerulopathy
KR20090127433A (ko) * 2007-04-05 2009-12-11 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
BR112020003247A2 (pt) 2020-08-18
JP2020531425A (ja) 2020-11-05
JP7410017B2 (ja) 2024-01-09
AU2018317812A1 (en) 2020-02-20
US11072591B2 (en) 2021-07-27
ES2885573T3 (es) 2021-12-14
LT3668856T (lt) 2021-09-27
HRP20211326T1 (hr) 2021-11-26
RS62267B1 (sr) 2021-09-30
PT3668856T (pt) 2021-09-15
HUE055732T2 (hu) 2021-12-28
EP3668856B1 (en) 2021-06-23
CA3072854A1 (en) 2019-02-21
EP3668856A1 (en) 2020-06-24
RU2020110818A3 (da) 2021-10-11
SI3668856T1 (sl) 2021-11-30
PL3668856T3 (pl) 2021-12-13
AU2018317812B2 (en) 2021-04-15
WO2019034729A1 (en) 2019-02-21
CY1124577T1 (el) 2022-07-22
CN110997651A (zh) 2020-04-10
KR20200041915A (ko) 2020-04-22
US20200231555A1 (en) 2020-07-23
KR102661367B1 (ko) 2024-04-29
CN110997651B (zh) 2023-01-03
RU2020110818A (ru) 2021-09-17
AU2018317812C1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3303396T3 (da) Antistoffer mod ox40 og anvendelser deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3303379T3 (da) Tigit-bindende midler og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3842429T3 (da) Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK3668856T3 (da) Hidtil ukendte tetrazolforbindelser og anvendelse deraf til behandling af tuberkulose
DK3573611T3 (da) Amidforbindelser og anvendelse deraf
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf